Previous studies have identified the DNA methylation alterations of ZNF132 in breast cancer, esophageal squamous cell carcinoma (ESCC), oropharyngeal squamous cell carcinoma, and prostate cancer (Lleras et al., 2011; Abildgaard et al., 2012; Stefansson et al., 2015; Jiang et al., 2018). This evidence concerns the gene ZNF132 and prostate cancer.